Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H23N5O.2ClH |
| Molecular Weight | 386.319 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CN1C[C@@H]2C[C@@H](C[C@@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4
InChI
InChIKey=KOYCUQMOCJHRJC-UHFFFAOYSA-N
InChI=1S/C17H23N5O.2ClH/c1-21-9-12-7-11(8-13(10-21)22(12)2)18-17(23)16-14-5-3-4-6-15(14)19-20-16;;/h3-6,11-13H,7-10H2,1-2H3,(H,18,23)(H,19,20);2*1H
| Molecular Formula | C17H23N5O |
| Molecular Weight | 313.3974 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/e94550c93cd70fe748e6982b3439ad3b.htmlCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/18633256
http://www.lifescience.co.jp/yk/yk04/nov/ab5.htm
Sources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/e94550c93cd70fe748e6982b3439ad3b.html
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/18633256
http://www.lifescience.co.jp/yk/yk04/nov/ab5.htm
Indisetron dihydrochloride (N-3389) was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on January 29, 2004. It was co-developed and co-marketed as Sinseron by Kyorin & Yakult Honsha in Japan. Indisetron is a dual serotonin 5-HT3 and 5-HT4 receptor antagonist. It is indicated for the treatment of prophylaxis of chemotherapy-induced nausea and vomiting, it’s administered once daily. Indisetron is metabolized in the liver, and CYP1A1, CYP2C9, CYP2D6, and CYP3A4 are involved in its metabolism. However, indisetron is unlikely to cause drug interactions at clinical doses because the effective plasma concentrations are lower than those necessary for inhibiting the metabolic enzymes. No drug interaction has been reported. Indisetron antagonizes 5-HT4 receptors, as well as 5-HT3 receptors, and this characteristic is expected to contribute to its clinical efficacy.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2111332 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7698198 |
8.77 null [pKi] | ||
Target ID: CHEMBL1875 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7698198 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Sinseron Approved UseUnknown Launch Date2004 |
|||
| Preventing | Sinseron Approved UseUnknown Launch Date2004 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
34.7 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
59 ng/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
164.59 ng/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
339.1 ng/mL |
32 mg single, oral dose: 32 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
128.5 ng/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
185.6 ng/mL |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
200.6 ng/mL |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
277.3 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
438.4 ng × h/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1208.34 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2488.7 ng × h/mL |
32 mg single, oral dose: 32 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1103.6 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1229.7 ng × h/mL |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1664.3 ng × h/mL |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.93 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.4 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.25 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.09 h |
32 mg single, oral dose: 32 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.04 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
5.1 h |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.71 h |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
21.5% |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23.5% |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
INDISETRON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Constipation... |
8 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Headache... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Constipation | grade 1, 4.8% | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Headache | grade 1, 4.8% | 8 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer]. | 2008-07 |
|
| Antagonistic activities of N-3389, a newly synthesized diazabicyclo derivative, at 5-HT3 and 5-HT4 receptors. | 1994-12-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18633256
8 mg once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7698198
N-3389 (INDISETRON ) (3 x 10(-7)-3 x 10(-6) M) was found to inhibit the increase of electrically stimulated twitch responses induced by 5-HT (10(-8) M) longitudinal muscle myenteric plexus preparation of the guinea-pig ileum
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:45:46 GMT 2025
by
admin
on
Mon Mar 31 18:45:46 GMT 2025
|
| Record UNII |
NBN3HB12DW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C94726
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB27486
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
PRIMARY | |||
|
C95285
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
PRIMARY | |||
|
160472-97-9
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
PRIMARY | |||
|
NBN3HB12DW
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
PRIMARY | |||
|
9864962
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
PRIMARY | |||
|
100000091636
Created by
admin on Mon Mar 31 18:45:46 GMT 2025 , Edited by admin on Mon Mar 31 18:45:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |